Twist Bioscience Stock Rallies As AI Drug Deals Drive Re‑Rating

Twist Bioscience Corporation stocks have been trading up by 8.92 percent after a pivotal synthetic DNA technology advancement.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For TWST Traders

Shares of Twist Bioscience (TWST) have surged as traders respond to a major antibody data deal with Eli Lilly’s AI/ML drug discovery platform, TuneLab.
Leerink boosted its TWST price target twice, from $120 to $160 and then to $190, while maintaining an Outperform rating and citing rising pharma adoption.
Guggenheim more than doubled its TWST target from $107 to $212, a sharp reset of upside expectations ahead of Q3 earnings.
UBS started coverage of TWST at Neutral but with a relatively high $144 target, underscoring sector growth potential in life science tools.
Twist Bioscience is leaning into a “picks-and-shovels” role for AI drug discovery and guiding toward adjusted EBITDA breakeven by Q4 FY26.

Live Update At 15:03:39 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 8.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TWST has been on a strong run. In the latest session, Twist Bioscience opened near $193 and closed at $205.85, pushing toward the top of the daily range and extending a multi-week uptrend from around $120 in mid-September 2026. The tape shows steady buying rather than a single spike, a pattern momentum traders like to see.

On the intraday 5‑minute chart, TWST spent most of the afternoon grinding between $200 and $206, with higher lows and a firm close at the high of the day. That intraday strength, especially after a big prior move, often signals shorts covering and late buyers chasing.

Fundamentally, Twist Bioscience is still a high‑growth, money‑losing story. Quarterly revenue is about $118.4M with a healthy 52% gross margin, but EBIT margin is roughly ‑32% and net income for the last reported quarter was about ‑$35.1M. The company is burning cash, with free cash flow around ‑$8.6M for the quarter, yet it generated positive operating cash flow and holds roughly $119.6M in cash.

More Breaking News

Leverage is modest, with total debt to equity at 0.21 and a current ratio of 2.7, which gives TWST room to keep funding growth. Management is targeting adjusted EBITDA breakeven in Q4 FY26. For traders, that means the story is still about revenue growth, AI leverage, and multiple expansion rather than current profits.

Why Traders Are Watching TWST Right Now

The core of the TWST story in late 2026 is simple: Wall Street is rapidly re‑rating Twist Bioscience around AI‑driven drug discovery.

The marquee catalyst is the agreement with Eli Lilly. Twist Bioscience will provide antibody characterization data and related services into Lilly’s AI/ML TuneLab platform, with TWST’s wet‑lab protocols feeding experimental data into models such as AbLab. For traders, this is textbook “picks‑and‑shovels” exposure to AI: TWST doesn’t have to guess which drug wins; it sells the data and tools to the whole ecosystem.

The market reaction to the Lilly TuneLab news was sharp. Multiple headlines noted that Twist Bioscience shares jumped several percent, including a move of more than 4%, as trading volume picked up after the collaboration hit the wires on 2026/09/16. AI plus a big‑pharma logo remains one of the strongest narrative combos in this market, and TWST is tapping directly into that.

Analysts have followed with aggressive target hikes. Leerink first took its TWST target from $120 to $160 on 2026/09/17, then pushed it again to $190 on 2026/09/29, both times reaffirming an Outperform rating. The firm called out conservative revenue assumptions and increasing confidence that pharma will adopt the Twist Bioscience platform more broadly.

Guggenheim went even further on 2026/10/01, more than doubling its target from $107 to $212 while keeping a Buy rating. That kind of step‑change in a price target tends to reset how traders think about the upside range, especially heading into Q3 earnings for diagnostics and life science tools names.

UBS offers a more cautious angle. It initiated TWST at Neutral on 2026/09/09, but with a $144 target that still sits well above older consensus numbers. That suggests valuation is rich after the rally, yet the long‑term growth story in life science tools, and in Twist Bioscience specifically, remains compelling for many on the Street.

Layer on confirmation that pilot work with Anthropic on AI‑designed mini‑binder proteins is already baked into fiscal 2027 orders, and TWST starts to look like a central data player in multiple AI pipelines, not a one‑off story.

Conclusion

For active traders, TWST now trades like a pure‑play momentum name wrapped around a serious AI and biotech infrastructure story. Twist Bioscience is tying its fate to some of the strongest current themes in the market: AI‑enabled drug discovery, big‑pharma partnerships, and high‑margin data services. At the same time, the company is reporting strong revenue growth, expanding margins, and a clear target of adjusted EBITDA breakeven by Q4 FY26.

That mix of narrative and numbers is exactly what has driven the latest surge in Twist Bioscience share price. The Lilly TuneLab deal validated TWST’s technology with a top‑tier partner and gave the Street a reason to raise targets. Leerink’s moves to $160 and then $190, Guggenheim’s jump to $212, and UBS’s Neutral at $144 all reinforce that the TWST story is now on the radar of major research desks.

There are still risks. Twist Bioscience is unprofitable, valuation is rich on metrics like price‑to‑sales, and insider selling — including a recent Form 4 from CEO Emily Leproust — will keep some traders cautious, even though she still holds a large stake. But for now, momentum is clearly on the side of TWST bulls. That’s precisely where short‑term traders tend to focus: the price action and near‑term catalysts in front of them. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” For many momentum‑oriented TWST traders, that mindset of reacting to what the chart is showing today — rather than guessing about distant outcomes — is key to shaping their trading plans.

As Tim Sykes loves to remind traders, “Patterns repeat, but they don’t always complete — that’s why you cut losses quickly and never fall in love with a stock.” TWST offers a powerful story and strong trend, yet the job for traders is the same as always: respect the chart, track the catalysts, and manage risk first. This analysis is for educational and research purposes only, and not trading advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!